Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Osteoporosis International
Published in: Osteoporosis International 3/2015

01-03-2015 | Original Article

Increased bone resorption during tenofovir plus lopinavir/ritonavir therapy in Chinese individuals with HIV

Authors: E. Hsieh, L. Fraenkel, W. Xia, Y. Y. Hu, Y. Han, K. Insogna, M. T. Yin, J. Xie, T. Zhu, T. Li

Published in: Osteoporosis International | Issue 3/2015

Login to get access

Abstract

Summary

We sought to evaluate the effects of antiretroviral therapy on skeletal metabolism in Chinese individuals with human immunodeficiency virus. Patients switched to tenofovir/lamivudine + lopinavir/ritonavir after treatment failure had an increase in bone resorption marker levels by nearly 60 %, which is greater than the magnitude previously described in non-Chinese populations.

Introduction

Few studies have evaluated the effects of antiretroviral therapy on skeletal metabolism in Asian populations infected with human immunodeficiency virus (HIV).

Methods

We performed a secondary analysis of bone turnover markers (BTM) at baseline and 2 years in stored plasma samples collected from 2/2009 to 1/2013 as part of a multi-center trial. Two groups were compared: (1) treatment-naïve patients initiated on zidovudine (AZT)/lamivudine (3TC) plus nevirapine (NVP) and (2) patients who failed first-line therapy and were switched to tenofovir (TDF)/3TC plus lopinavir/ritonavir (LPVr). Tests included the bone resorption marker, C-terminal cross-linking telopeptide of type-1 collagen (CTX), and the bone formation marker procollagen type 1 N-terminal propeptide (P1NP).

Results

In the TDF/3TC + LPVr group, samples were available from 59 patients at baseline and 56 patients at 2 years. Of these, 36 patients had samples available from both time points. In the AZT/3TC + NVP group, plasma samples were analyzed from 82 participants at baseline and of those, 61 had samples at 2 years. Median change over 2 years was greater in the TDF/3TC + LPVr group for both CTX (+0.24 ng/mL, interquartile ranges (IQR) 0.10–0.43 vs. +0.09 ng/mL, IQR −0.03 to 0.18, p = 0.001) and P1NP (+25.5 ng/mL, IQR 2.4–51.3 vs. +7.11 ng/mL, IQR −4.3 to 21.6, p = 0.012). Differences remained after adjusting for potential confounders in the multivariable analysis.

Conclusions

Switching to TDF/3TC + LPVr after treatment failure resulted in greater increases in BTMs than initiation with AZT/3TC + NVP in Chinese patients with HIV. Following this change, bone resorption marker levels increased by nearly 60 %, which is greater than the 25–35 % increase from baseline described previously in non-Chinese populations. Further studies are warranted to elucidate these findings.
Literature
1.
Mondy K, Yarasheski K, Powderly WG et al (2003) Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis 36(4):482–901CrossRefPubMed
2.
Piso RJ, Rothen M, Rothen JP, Stahl M (2011) Markers of bone turnover are elevated in patients with antiretroviral treatment independent of the substance used. J Acquir Immune Defic Syndr 56(4):320–324CrossRefPubMed
3.
Yin MT, McMahon DJ, Ferris DC et al (2010) Low bone mass and high bone turnover in postmenopausal human immunodeficiency virus-infected women. J Clin Endocrinol Metab 95:620–629CrossRefPubMedCentralPubMed
4.
Van Vonderen M.G., Mallon P, Murray B, et al. Changes in bone biomarkers in antiretroviral naïve HIV-infected men randomized to nevirapine/lopinavir/ritonavir or zidovudine/lamivudine /lopinavir/ritonavir help explain limited loss of bone mineral density over first 12 months after antiretroviral therapy initiation. 18th Conference on Retroviruses and Opportunistic Infections. Feb 27-Mar 2, 2011. Boston, MA.
5.
Squires KE, Gulick R, Tebas P et al (2000) A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I). AIDS 14(11):1591–1600CrossRefPubMed
6.
Stellbrink HJ, Orkin C, Arribas JR et al (2010) Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis 51(8):963–972CrossRefPubMed
7.
8.
Brown TT, McComsey GA, King MS, Qaqish RB, Bernstein BM, da Silva BA (2009) Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr 51:554–561CrossRefPubMed
9.
Hansen AB, Obel N, Nielson H, Pedersen C, Gerstoft J (2011) Bone mineral density changes in protease inhibitor-sparing vs. nucleoside reverse transcriptase inhibitor-sparing highly active antiretroviral therapy: data from a randomized trial. HIV Medicine 12:157–165CrossRefPubMed
10.
Guerri-Fernandez R, Vestergaard P, Carbonell C et al (2013) HIV infection is strongly associated with hip fracture risk, independently of age, gender and comorbidities: a population-based cohort study. J Bone Miner Res 28:1259–1263CrossRefPubMed
11.
Hansen AB, Gerstoft J, Kronborg F et al (2012) Incidence of low and high-energy fractures in persons with and without HIV infection: a Danish population-based cohort study. AIDS 26:285–293CrossRefPubMed
12.
Womack JA, Goulet JL, Gibert C et al (2011) Increased risk of fragility fractures among HIV infected compared to uninfected male veterans. PLoS One 6:e17217CrossRefPubMedCentralPubMed
13.
Triant VA, Brown TT, Lee H, Grinspoon SK (2008) Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab 93:3499–3504CrossRefPubMedCentralPubMed
14.
McComsey GA, Kitch D, Daar ES et al (2011) Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: AIDS Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis 203(12):1791–1801CrossRefPubMedCentralPubMed
15.
Bedimo R, Maalouf NM, Zhang S, Drechsler H, Tebas P (2012) Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents. AIDS 26:825–831CrossRefPubMed
16.
Gallant JE, Staszewski S, Pozniak AL et al (2004) Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. Journal Am Med Assoc 292:191–201CrossRef
17.
Fux CA, Rauch A, Simcock M et al (2008) Tenofovir use is associated with an increase in serum alkaline phosphatase in the Swiss HIV Cohort Study. Antivir Ther 13:1077–1082PubMed
18.
Childs KE, Fishman SL, Constable C et al (2010) Short communication: inadequate vitamin D exacerbates parathyroid hormone elevations in tenofovir users. AIDS Res Hum Retroviruses 26(8):855–859CrossRefPubMedCentralPubMed
19.
Masiá M, Padilla S, Robledano C, López N, Ramos JM, Gutiérrez F (2012) Short communication: early changes in parathyroid hormone concentrations in HIV-infected patients initiating antiretroviral therapy with tenofovir. AIDS Res Hum Retroviruses 28(3):242–246CrossRefPubMed
20.
Focà E, Motta D, Borderi M et al (2012) Prospective evaluation of bone markers, parathormone and 1,25-(OH)2 vitamin D in HIV positive patients after the initiation of tenofovir/ emtricitabine with atazanavir/ritonavir or efavirenz. BMC Infectious Diseases 12:38CrossRefPubMedCentralPubMed
21.
Duvivier C, Kolta S, Assoumou L et al (2009) Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. AIDS 23(7):817–824CrossRefPubMed
22.
Rivas P, Górgolas M, García-Delgado R, Díaz-Curiel M, Goyenechea A, Fernández-Guerrero ML (2008) Evolution of bone mineral density in AIDS patients on treatment with zidovudine/lamivudine plus abacavir or lopinavir/ritonavir. HIV Medicine 9:89–95CrossRefPubMed
23.
Jain RG, Lenhard JM (2002) Select HIV protease inhibitors alter bone and fat metabolism ex vivo. J Biol Chem 277(22):19247–19250CrossRefPubMed
24.
Hernandez-Vallejo SJ, Beaupere C, Larghero J, Capeau J, Lagathu C (2013) HIV protease inhibitors induce senescence and alter osteoblastic potential of human bone marrow mesenchymal stem cells: beneficial effect of pravastatin. Aging Cell. doi:10.​1111/​acel.​12119 PubMed
25.
Zhang F, Dou Z, Ma Y et al (2011) Effect of earlier initiation of antiretroviral treatment and increased treatment coverage on HIV-related mortality in China: a national observational cohort study. Lancet Infect Dis 11(7):516–524CrossRefPubMed
26.
Dou Z, Chen RY, Xu J et al (2010) Changing baseline characteristics among patients in the China National Free Antiretroviral Treatment Program, 2002–09. Int J Epidemiol 39:ii56–ii64CrossRefPubMedCentralPubMed
27.
28.
29.
Von Wyl V, Cambiano V, Jordan MR et al (2012) Cost-effectiveness of tenofovir instead of zidovudine for use in first-line antiretroviral therapy in settings without virological monitoring. PLoS ONE 7(8):e42834CrossRef
30.
Kou H, Du X, Li Y, Xie J, Qiu Z et al (2013) Comparison of nevirapine plasma concentrations between lead-in and steady-state periods in Chinese HIV-infected patients. PLoS ONE 8(1):e52950CrossRefPubMedCentralPubMed
31.
Cao Y, Han Y, Xie J et al (2013) Impact of a tenofovir disoproxil fumarate plus ritonavir-boosted protease inhibitor-based regimen on renal function in HIV-infected individuals: a prospective, multicenter study. BMC Infectious Diseases 13:301CrossRefPubMedCentralPubMed
32.
Cotter A, Vrouenraets SME, Brady JJ et al (2013) Impact of switching from zidovudine to tenofovir disoproxil fumarate on bone mineral density and markers of bone metabolism in virologically suppressed HIV-1 infected patients; a substudy of the PREPARE study. J Clin Endocrinol Met 98(4):1659–1666CrossRef
33.
Haskelberg H, Hoy JF, Amin J et al (2012) Changes in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudine. PLoS ONE 7(6):e38377CrossRefPubMedCentralPubMed
34.
Rasmussen TA, Jensen D, Tolstrup M et al (2012) Comparison of bone and renal effects in HIV-infected adults switching to abacavir or tenofovir based therapy in a randomized trial. PLoS ONE 7(3):e32445CrossRefPubMedCentralPubMed
35.
de Menezes Barbosa EG, de Paula FJ, Machado AA, de Assis PF, Barbosa Júnior F, Navarro AM (2013) Impact of anitretroviral therapy on bone metabolism markers in HIV-seropositive patients. Bone 57(1):62–67CrossRefPubMed
36.
Hu CY, Liu YM, Liu Y et al (2013) Pharmacokinetics and tolerability of tenofovir disoproxil fumarate 300 mg once daily: an open-label, single- and multiple-dose study in healthy Chinese subjects. Clin Ther
37.
Li Y, Uenishi R, Hase S et al (2010) Explosive HIV-1 subtype B′ epidemics in Asia driven by geographic and risk group founder events. Virology 401:223–227CrossRef
38.
Li L, Sun GQ, Liang SJ et al (2013) Different distribution of HIV-1 subtype and drug resistance were found among treatment naïve individuals in Henan, Guangxi, and Yunnan Province of China. PLoS ONE 8(10):e75777CrossRefPubMedCentralPubMed
39.
Van Den Bout-Van Den Beukel CJ, Fievez L, Michels M et al (2008) Vitamin D deficiency among HIV type 1-infected individuals in the Netherlands: effects of antiretroviral therapy. AIDS Res Hum Retroviruses 24(11):1375–1382CrossRef
40.
Havens PL, Stephensen CB, Hazra R et al (2012) Vitamin D3 decreases parathyroid hormone in HIV-infected youth being treated with tenofovir: a randomized, placebo-controlled trial. Clin Infect Dis 54(7):1013–1025CrossRefPubMedCentralPubMed
41.
Havens PL, Kiser JJ, Stephensen CB et al (2013) Association of higher plasma vitamin D binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: cause of a functional vitamin D deficiency? Antimicrob Agents and Chemother 57(11):5619–5628CrossRef
42.
Bech A, Van Bentum P, Nabbe K, Gisolf J, Richter C, De Boer H (2012) Fibroblast growth factor 23 in hypophosphataemic HIV-positive adults on tenofovir. HIV Med 13(9):558–563PubMed
Metadata
Title
Increased bone resorption during tenofovir plus lopinavir/ritonavir therapy in Chinese individuals with HIV
Authors
E. Hsieh
L. Fraenkel
W. Xia
Y. Y. Hu
Y. Han
K. Insogna
M. T. Yin
J. Xie
T. Zhu
T. Li
Publication date
01-03-2015
Publisher
Springer London
Published in
Osteoporosis International / Issue 3/2015
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-014-2874-3

Other articles of this Issue 3/2015

Osteoporosis International 3/2015 Go to the issue

Original Article

Predictors of 25(OH)D half-life and plasma 25(OH)D concentration in The Gambia and the UK

Original Article

Distribution of vertebral fractures varies among patients according to hip fracture type

Original Article

Ten-year incidences of self-reported non-vertebral fractures in Japanese patients with rheumatoid arthritis: discrepancy between disease activity control and the incidence of non-vertebral fracture

Editorial

The complex relationship between bone remodeling and the physical and material properties of bone

Original Article

Exercise characteristics influence femoral cross-sectional geometry: a magnetic resonance imaging study in elite female athletes

Review

Incorporating bazedoxifene into the treatment paradigm for postmenopausal osteoporosis in Japan